Validating the inactivation of viral pathogens with a focus on SARS-CoV-2 to safely transfer samples from high-containment laboratories
Frontiers in Cellular and Infection Microbiology · 2024
DOI: 10.3389/fcimb.2024.1292467 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Sankar Prasad Chaki und 3 weiteren Autor:innen. Beteiligte Einrichtung: Global Health Research Complex, Division of Research, Texas A&M University, College Station, TX, United States. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Pathogen leak from a high-containment laboratory seriously threatens human safety, animal welfare, and environmental security. Transportation of pathogens from a higher (BSL4 or BSL3) to a lower (BSL2) containment laboratory for downstream experimentation requires complete pathogen inactivation. Validation of pathogen inactivation is necessary to ensure safety during transportation. This study established a validation strategy for virus inactivation.
Methods
SARS-CoV-2 wild type, delta, and omicron variants underwent heat treatment at 95°C for 10 minutes using either a hot water bath or a thermocycler. To validate the inactivation process, heat-treated viruses, and untreated control samples were incubated with A549-hACE2 and Vero E6-TMPRSS2-T2A-ACE2 cells. The cells were monitored for up to 72 hours for any cytopathic effects, visually and under a microscope, and for virus genome replication via RT-qPCR. The quality of post-treated samples was assessed for suitability in downstream molecular testing applications.
Results
Heat treatment at 95°C for 10 minutes effectively inactivated SARS-CoV-2 variants. The absence of cytopathic effects, coupled with the inability of virus genome replication, validated the efficacy of the inactivation process. Furthermore, the heat-treated samples proved to be qualified for COVID-19 antigen testing, RT-qPCR, and whole-genome sequencing.
Discussion
By ensuring the safety of sample transportation for downstream experimentation, this validation approach enhances biosecurity measures. Considerations for potential limitations, comparisons with existing inactivation methods, and broader implications of the findings are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Global Health Research Complex, Division of Research, Texas A&M University, College Station, TX, United States.
- Department of Biological Sciences, Texas A&M University, College Station, TX, United States.
- Department of Molecular Pathogenesis and Immunology, Texas A&M University, College Station, TX, United States.
Zitieren
APA
Chaki, S. P., Kahl-McDonagh, M. M., Neuman, B. W., & Zuelke, K. A. (2024). Validating the inactivation of viral pathogens with a focus on SARS-CoV-2 to safely transfer samples from high-containment laboratories. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1292467
Vancouver
Chaki SP, Kahl-McDonagh MM, Neuman BW, Zuelke KA. Validating the inactivation of viral pathogens with a focus on SARS-CoV-2 to safely transfer samples from high-containment laboratories. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1292467
BibTeX
@article{Chaki2024,
author = {Chaki, Sankar Prasad and Kahl-McDonagh, Melissa M and Neuman, Benjamin W and Zuelke, Kurt A},
title = {Validating the inactivation of viral pathogens with a focus on SARS-CoV-2 to safely transfer samples from high-containment laboratories},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2024},
doi = {10.3389/fcimb.2024.1292467}
}
EUVIMED